Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 7 | Molecular Autism

Fig. 7

From: Rescuing epileptic and behavioral alterations in a Dravet syndrome mouse model by inhibiting eukaryotic elongation factor 2 kinase (eEF2K)

Fig. 7

Pharmacological inhibition of eEF2K activity rescues the epileptic phenotype in Scn1a ± mice and improve autistic-like behavior and memory impairment.A Experimental timeline. B Representative western blots and relative quantification show a significantly reduction of phosphorylated eEF2 and no differences in eEF2 expression levels in total homogenate of hippocampus (left) and cerebral cortex (right) of Scn1a ± mice after a chronic treatment of 10 days with 1 mg/day dose of A484954 compared with placebo. All data are presented as mean ± SEM. N = 5 per group. Statistical analysis **p < 0.01 versus corresponding Scn1a ± treated with placebo; Unpaired two-tailed t-test. C Representative EEG traces (a 60 min registration is shown) in basal condition and at 9 days of treatment of a Scn1a ± mouse treated with placebo or A484954. D Quantification of the number of EEG spikes calculated in percentage per 24 h in basal condition and at 3, 6 and 9 days of treatment. Significant reduction of the number of EEG spikes across the three EEG recording in Scn1a ± mice treated with A484954. No difference in number of EEG spikes in Scn1a ± mice treated with placebo. Scn1a ± mice treated with A484954 n = 5, Scn1a ± mice treated with placebo n = 5. Statistical analysis **p < 0.01 versus corresponding EEG basal, $p < 0.05 versus corresponding EEG at 3 days of treatment; Friedman test. E Significant reduction in repetitive grooming behavior in Scn1a ± mice before and after treatment with A484954 and in Scn1a ± mice treated with A484954 compared with Scn1a ± mice treated with placebo. Repetitive grooming is evaluated as time spent in self-grooming over 10 min observations. Data are presented as mean ± SEM. N = 5 per group. Statistical analysis **p < 0.01 versus corresponding Scn1a ± mice before treatment with A484954; $$p < 0.01 versus corresponding Scn1a ± mice after treatment with placebo; Two-way ANOVA. F Discrimination index evaluated in the novel object recognition test at the end of treatment shows a memory improvement in Scn1a ± mice treated with A484954 compared with animals treated with placebo at 120 min and 24 h after familiarization phase. Data are presented as mean ± SEM. N = 5 per group. Statistical analysis *p < 0.05, **p < 0.01 versus corresponding Scn1a ± mice treated with placebo. Unpaired two-tailed t-test for 5 min and 120 min; Two-tailed Mann–Whitney test for 24 h

Back to article page